Dasiglucagon
- Generic Name
- Dasiglucagon
- Brand Names
- Zegalogue
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1544300-84-6
- Unique Ingredient Identifier
- AD4J2O47FQ
- Background
Dasiglucagon is a glucagon analog that acts to increase blood sugar levels. It consists of 29 amino acids similar to endogenous glucagon; however, it contains seven substituted amino acids for improved physical and chemical stability in its drug formulation. In March 2021, the FDA approved dasiglucagon to treat severe hypoglycemia in patients six years and o...
- Indication
Dasiglucagon is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.
- Associated Conditions
- Severe Hypoglycemia
- Associated Therapies
- -
FDA Issues Second CRL for Dasiglucagon (Zegalogue) in Congenital Hyperinsulinism
The FDA issued a Complete Response Letter for dasiglucagon (Zegalogue) for hypoglycemia prevention/treatment in pediatric congenital hyperinsulinism patients due to third-party manufacturing facility inspection timing issues. Zealand Pharma is committed to resolving these issues to bring dasiglucagon to patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath